Comments on: Clinical Trial Update: Boswellia for Inflammatory Bowel Disease — 2026 Data

By: Vikram Bansal

Vikram Bansal — Tue, 15 Sep 2026 17:02:21 +0000

the AKBA percentage matters a lot for efficacy. is the standard Boswellia extract in India typically 65% or 30

Naveen Sinha — Sun, 13 Sep 2026 10:35:13 +0000

Needs more proof

Jessica Lee — Fri, 11 Sep 2026 04:20:12 +0000

does Boswellia interact with immunosuppressants. the article doesn’t address combination therapy asked this just now

Susan Choudhary — Sun, 06 Sep 2026 09:26:34 +0000

In reply to Mahesh Yadav. does Boswellia interact with immunosuppressants. the article doesnt address combination therapy asked this recently

Susan Johnson — Sat, 05 Sep 2026 19:27:42 +0000

The safest part of the Trial Update advice is keeping it simple. This would be easier to follow with a one-week sample plan.

Prakash Menon — Fri, 04 Sep 2026 04:26:23 +0000

the 2026 IBD data looks promising but effect sizes in those trials are modest. don’t stop your gastroenterologist treatment asked this earlier

Chris Martin — Tue, 01 Sep 2026 15:43:04 +0000

In reply to Naveen Yadav. for joint inflammation vs IBD, is the dosing protocol different or same Boswellia preparation asked this just now

Asha Yadav — Mon, 24 Aug 2026 14:46:27 +0000

for joint inflammation vs IBD, is the dosing protocol different or same Boswellia preparation

Christopher Adams — Sat, 15 Aug 2026 11:40:37 +0000

the AKBA percentage matters a lot for efficacy. is the standard Boswellia extract in India typically 65% or 30

Megan Brown — Thu, 13 Aug 2026 05:33:52 +0000

for joint inflammation vs IBD, is the dosing protocol different or same Boswellia preparation asked this recently